ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Shire has agreed to pay $750 million to acquire Advanced BioHealing, a maker of a bioengineered skin substitute used in the treatment of diabetic foot ulcers. ABH had sales last year of $146 million, which Shire figures is about 5% of the potential market for slow-healing diabetic foot ulcer treatments. ABH was on the verge of making an initial public offering of stock when the deal was announced. Shire says ABH will be the core of a new business in regenerative medicine.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X